First Wave BioPharma, Inc. (FWBI)

2,8500 -0,0100 (-0,35%) Al cierre: 04:00PM EDT

First Wave BioPharma, Inc.

777 Yamato Road
Suite 502
Boca Raton, FL 33431
United States
(561) 589-7020
https://www.firstwavebio.com

Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 9

Ejecutivos clave

Nombre	Título	Paga	Ejecutado	Año de nacimiento
Mr. James R. Sapirstein M.B.A., R.Ph.	CEO & Chairman	906,2k	N/A	1961
Ms. Sarah Romano CPA	Chief Financial Officer	624,88k	N/A	1981
Dr. Jack A. Syage Ph.D.	President, COO & Director	N/A	N/A	1955
Ms. Amy Chandler-Skerkis	Vice President of Regulatory Affairs, QA & Compliance	N/A	N/A	1969
Mr. Martin Krusin M.B.A.	Senior Vice President of Corporate Development	N/A	N/A	N/A

Los importes son a partir de 31 de diciembre de 2023 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

First Wave BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of targeted and non-systemic therapies for the treatment of patients with gastrointestinal diseases. Its product candidates include latiglutenase, a targeted oral biotherapeutic for celiac disease designed to breakdown gluten into non-immunogenic peptides; biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients; capeserod, a selective 5-HT4 receptor partial agonist to treat gastroparesis; and niclosamide, an oral small molecule with anti-inflammatory properties for patients with inflammatory bowel diseases, such as ulcerative colitis and Crohn's disease. It is also developing CypCel, a disease management tool for monitoring the intestinal health of recovering celiac disease patients. The company was formerly known as AzurRx BioPharma, Inc. and changed its name to First Wave BioPharma, Inc. in September 2021. First Wave BioPharma, Inc. was incorporated in 2014 and is headquartered in Boca Raton, Florida.

Gobierno corporativo

El ISS Governance QualityScore de First Wave BioPharma, Inc., a día N/A, es N/A. Las puntuaciones base son Auditoría: N/A; Tablero: N/A; Derechos de los accionistas: N/A; Compensación: N/A.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.